cbdMD, Inc. YCBD
0.47
0.01
2.17%
as of 25 Sep
- Market cap
- $4.8M
- P/E
- 55.3×
Follow YCBD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
78.82 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.34 | 0.39 | 0.64 | 0.25 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(16.09) | (10.70) | (14.96) | (20.21) | |
P/B ratio |
0.87 | 0.83 | 1.35 | 0.67 | |
Price to Tangible BV |
1.18 | 1.12 | 1.72 | 0.95 | |
EV/Sales |
0.37 | 0.39 | 0.60 | 0.27 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.45) | (3.12) | (5.87) | (3.62) | |
EV/FCF |
(3.09) | (2.84) | (5.19) | (3.08) | |
Quick Ratio |
1.26 | 1.42 | 1.62 | 1.03 | |
Current Ratio |
2.50 | 2.82 | 2.94 | 2.05 | |
Net Debt/EBITDA |
3.07 | 6.98 | (26.00) | 8.93 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.82 | 1.72 | 1.64 | 1.83 | |
Operating CF/Net income |
0.37 | 0.82 | 2.50 | 0.35 | |
Capex/Depreciation |
(0.04) | (0.01) | (0.40) | (0.01) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.17 | 0.19 | 0.16 | 0.20 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.09% | |
Graham Net Nets |
0.39 | 0.70 | 0.44 | 0.69 | |
Graham Number |
0.38 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
1.27% | (12.36%) | (141.59%) | (300.12%) | |
Free Cash Flow Yield |
(34.86%) | (35.26%) | (18.11%) | (35.06%) | |
Revenue per Share |
0.52 | 0.54 | 0.56 | 1.17 | |
Operating CF per Share |
(0.04) | (0.07) | (0.09) | (0.06) | |
Capex per Share |
0.00 | 0.00 | (0.02) | 0.00 | |
Free Cash Flow per Share |
(0.04) | (0.07) | (0.11) | (0.06) | |
Cash per Share |
0.20 | 0.25 | 0.38 | 0.56 | |
Shareholders Equity per Share |
0.77 | 0.89 | 1.00 | 1.80 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.77 | 0.89 | 1.00 | 1.80 | |
Free Cash Flow |
(0.46) | (0.73) | (0.98) | (0.24) | |
Working Capital |
4.62 | 5.42 | 5.39 | 3.36 | |
Capital Expenditures |
(0.02) | (0.01) | (0.16) | 0.00 | |
Net Current Asset Value |
2.76 | 5.42 | 5.39 | 3.36 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.03 | 0.00 | |
Net Profit Margin |
(21.57%) | (15.55%) | (6.47%) | (14.40%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.36 | 1.31 | 1.20 | 1.01 | |
Average Payables |
1.35 | 1.34 | 1.02 | 1.36 | |
Average Inventory |
3.04 | 2.99 | 2.55 | 2.55 | |
Average Assets |
11.52 | 11.60 | 11.66 | 10.50 | |
Average Common Equity |
7.16 | 4.97 | 5.39 | 4.59 |
Columns are period end dates